Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Expanded access is currently available for this treatment.
Verified November 2016 by Seattle Genetics, Inc.
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:
NCT01196208
First received: September 3, 2010
Last updated: November 14, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is currently available for this treatment.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: No date given